Macular disease - AMD

The Centre for Eye Research Australia (CERA) has established Cerulea Clinical Trials, a new specialist ophthalmic clinical trial facility in...

Optometrists have an opportunity to maximise care for their patients after they depart the consulting room thanks to patient support...

People often turn to supplements or superfoods to ward off macular disease or prevent its progression, but new Australian nutritional...

For optometrist Martin Robinson, iCare’s EIDON fundus camera has supercharged his practice and is an example of superior ergonomics, top-tier...

The Australian eyecare sector is challenging the idea that vision loss with age is inevitable. This, combined with cutting-edge research...

ZEISS has completed the acquisition of D.O.R.C. (Dutch Ophthalmic Research Center) that includes the EVA NEXUS platform, one of the...

A single-dose gene therapy for neovascular age-related macular degeneration (nAMD) is now in Phase 3 clinical trials and, if approved,...

RANZCO’s Referral Pathway for Age-Related Macular Degeneration (AMD) Management has been updated as Australia gears up for the first approved...

A UNSW-developed molecule that could be administered via an eye drop for neovascular age-related macular degeneration (nAMD) is being commercialised...

  Bayer’s high dose aflibercept 8 mg – now approved in the European Union and US – has been labelled...